Skip to content
10-Q

Quarterly Report

CIDARA THERAPEUTICS, INC.

0001610618-25-000047

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 12.97M sh
Shares Diluted Q1 2025 · Mar 31, 2025 14.18M sh
Shares Diluted Q1 2025 · Mar 31, 2024 4.54M sh
Capex Q1 2025 · Mar 31, 2025 $0
Capex Q1 2025 · Mar 31, 2024 $23K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$21.95M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$6.64M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $168.15M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $189.83M
Stockholders Equity Q1 2025 · Mar 31, 2025 $141.68M
Stockholders Equity Q1 2025 · Dec 31, 2024 $163.31M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$17.78M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$8.21M
Current Liabilities Q1 2025 · Mar 31, 2025 $48.81M
Current Liabilities Q1 2025 · Dec 31, 2024 $49.55M
Total Liabilities Q1 2025 · Mar 31, 2025 $50.05M
Total Liabilities Q1 2025 · Dec 31, 2024 $51.49M
Current Assets Q1 2025 · Mar 31, 2025 $188.85M
Current Assets Q1 2025 · Dec 31, 2024 $210.74M
Total Assets Q1 2025 · Mar 31, 2025 $191.73M
Total Assets Q1 2025 · Dec 31, 2024 $214.8M
Eps Diluted Q1 2025 · Mar 31, 2025 −$1.66
Eps Diluted Q1 2025 · Mar 31, 2024 −$2.28
Eps Basic Q1 2025 · Mar 31, 2025 −$1.66
Eps Basic Q1 2025 · Mar 31, 2024 −$2.28
Sga Expense Q1 2025 · Mar 31, 2025 $6.18M
Sga Expense restated Q1 2025 · Mar 31, 2024 $3.6M
Rd Expense Q1 2025 · Mar 31, 2025 $24.6M
Rd Expense restated Q1 2025 · Mar 31, 2024 $5.92M
Net Income Q1 2025 · Mar 31, 2025 −$23.48M
Net Income Q1 2025 · Mar 31, 2024 −$10.33M
Operating Income Q1 2025 · Mar 31, 2025 −$25.27M
Operating Income restated Q1 2025 · Mar 31, 2024 −$8.54M